the intussusceptum originates in the rectum, and the intussuscipiens includes part of the anal canal)
An Anatomico-Functional Classification of internal rectal intussusception has been described, with the argument that other factors apart from the height of intussusception above the anal canal appear to be important to predict symptomology. The parameters of this classification are anatomic descent, diameter of intussuscepted bowel, associated rectal hyposensitivity and associated delayed colonic transit:

Type 1: Internal recto-rectal intussusception
Type 1W Wide lumen
Type 1N Narrowed lumen
Type 2: Internal recto-anal intussusception
Type 2W Wide Lumen
Type 2N Narrowed lumen
Type 2M Narrowed internal lumen with associated rectal hyposensitivity or early megarectum
Type 3: Internal-external recto-anal intussusception

Diagnosis
History
Patients may have associated gynecological conditions which may require multidisciplinary management. History of constipation is important because some of the operations may worsen constipation. Fecal incontinence may also influence the choice of management. Physical examination
Rectal prolapse may be confused easily with prolapsing hemorrhoids. Mucosal prolapse also differs from prolapsing (3rd or 4th degree) hemorrhoids, where there is a segmental prolapse of the hemorrhoidal tissues at the 3, 7 and 11 oclock positions. Mucosal prolapse can be differentiated from a full thickness external rectal prolapse (a complete rectal prolapse) by the orientation of the folds (furrows) in the prolapsed section. In full thickness rectal prolapse, these folds run circumferential. In mucosal prolapse, these folds are radially. The folds in mucosal prolapse are usually associated with internal hemorrhoids. Furthermore, in rectal prolapse, there is a sulcus present between the prolapsed bowel and the anal verge, whereas in hemorrhoidal disease there is no sulcus.
Other anti-CD20 monoclonals
The efficacy and success of rituximab has led to some other anti-CD20 monoclonal antibodies being developed:

ocrelizumab, humanized (90%-95% human) B cell-depleting agent. ofatumumab (HuMax-CD20) a fully human B cell-depleting agent. Third-generation anti-CD20s such as obinutuzumab have a glycoengineered Fc fragment (Fc) with enhanced binding to Fc gamma receptors, which increase ADCC (antibody-dependent cellular cytotoxicity). This strategy for enhancing a monoclonal antibodys ability to induce ADCC takes advantage of the fact that the displayed Fc glycan controls the antibodys affinity for Fc receptors. References
External links
"Rituximab". Drug Information Portal. U.S. National Library of Medicine. "Discovery – Development of Rituximab". National Cancer Institute. 7 March 2014.